Keyphrases
Bioinformatics Methods
13%
Cancer Genomics
13%
Cancer Immunotherapy
25%
Cancer Therapy
23%
CD4+ T Cells
35%
CD8+ T Cells
46%
CDC1
20%
Cell Toxicity
30%
Cell-mediated
14%
Checkpoint Blockade Immunotherapy
26%
Circulating Tumor DNA (ctDNA)
20%
Dendritic Cells
13%
Downmodulation
12%
Epitope
15%
High-dimensional Analysis
20%
HIV Infection
12%
HIV Patients
22%
HIV-infected Cells
24%
Human Immunodeficiency Virus Type 1 (HIV-1)
44%
Immune Checkpoint
20%
Immune Checkpoint Therapy
33%
Immune System
18%
Immunogenicity
20%
Immunotherapeutics
20%
Inducible Nitric Oxide Synthase
13%
Infected Cells
33%
Intratumor
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
21%
Lysis
26%
MHC Class II
27%
Mutational Load
20%
Natural Killer Cells
80%
Neoantigen
91%
NKG2D
21%
Patient Selection
13%
Phase II Study
13%
Phenotypic Heterogeneity
20%
Primary T Cells
24%
Programmed Death-ligand 1 (PD-L1)
14%
Radiation Effects
20%
Small Cell Lung Cancer
13%
Synergize
13%
T Cells
29%
Tumor
66%
Tumor Antigen
15%
Tumor Cells
20%
Tumor Immunity
23%
Tumor Rejection
27%
Tumor-specific
17%
Tumor-specific mutant Antigens
20%
Immunology and Microbiology
B Cell
20%
Bioinformatics
13%
Blood Plasma
10%
Brentuximab Vedotin
10%
Cancer Immunotherapy
16%
CD155
10%
CD4
14%
Cell Antigen
10%
CX3CR1
15%
Cytolysis
11%
Cytotoxic T-Cell
60%
Degranulation
11%
Dendritic Cell
13%
DNA Damage Response
10%
Effector Cell
10%
Epitope
11%
Host Cell
10%
Human Immunodeficiency Virus
54%
Human Immunodeficiency Virus 1
57%
Human Immunodeficiency Virus Infection
12%
Immune Escape
10%
Immune Response
13%
Immune System
14%
Immunocompetent Cell
10%
Immunogenicity
17%
Immunotherapy
43%
Lenalidomide
10%
Macrophage
13%
Major Histocompatibility Complex
12%
Mutational Load
20%
Myeloid
20%
Natural Killer Cell
78%
Natural Killer Cell Mediated Cytotoxicity
10%
Neoantigen
100%
NKG2D
18%
Progression Free Survival
11%
Protein Binding
10%
RNA Sequence
16%
Sarcoma Cell Line
10%
T Cell
81%
T-Helper Cell
61%
Target Cell
12%
Tumor Antigen
13%
Tumor Cell
16%
Tumor Immunity
23%
Tumor Rejection
20%
Tumor-Associated Macrophage
12%
Tumor-Related Gene
10%
Vpr
11%
Vpu
20%
Medicine and Dentistry
Adaptive Immunity
8%
Adverse Event
5%
Atezolizumab
10%
Biological Marker
10%
Brentuximab Vedotin
10%
Cancer
31%
Cancer Immunotherapy
25%
Cancer Therapy
23%
Chemoradiotherapy
10%
Circulating Tumor DNA
20%
Clinical Finding
6%
CTLA-4
10%
Cytotoxic T-Cell
18%
Diffuse Large B-Cell Lymphoma
10%
Diseases
12%
External Beam Radiotherapy
6%
Hyaline Membrane Disease
10%
Immune Checkpoint Inhibitor
12%
Immune Response
10%
Immune System
5%
Immunotherapy
42%
In Vitro
6%
Induced Mutation
6%
Lenalidomide
10%
Lung Cancer
11%
Malignant Neoplasm
33%
Mutant Protein
9%
Mutational Load
20%
Neoplasm
38%
Nintedanib
10%
Non Small Cell Lung Cancer
40%
Overall Survival
10%
Patient Population
6%
Platelet Derived Growth Factor Receptor
6%
Progression Free Survival
9%
Protein P53
20%
Ramucirumab
10%
Sarcoma Cell Line
20%
Small Cell Lung Cancer
11%
Specific Tumor
22%
Systemic Therapy
13%
T Cell
21%
T-Cell Response
6%
T-Helper Cell
10%
Tumor Antigen
10%
Tumor Cell
11%
Tumor Infiltrating Lymphocyte
10%
Tumor Progression
6%
Tumor Rejection
13%
Tumor Treating Fields
10%
